Selected article for: "disease severity and viral load"
Author: Cho, Sung-Yeon; Lee, Hyeon-Jeong; Lee, Dong-Gun
Title: Infectious complications after hematopoietic stem cell transplantation: current status and future perspectives in Korea
  • Document date: 2018_2_27
    • ID: t9tysvr8_60
    Snippet: The Korean Journal of Internal Medicine Vol. 33, No. 2, March 2018 beyond the usual duration in cases of severe influenza LRTI [134, 139, 143] . Aerosolized ribavirin and intravenous immunoglobulin (IVIG) combination treatment significantly reduces RSV-LRTI-related mortality and is thus recommended by most guidelines [129, 137, 140, 141] . Although evidence is lacking, if aerosolized ribavirin cannot be used, oral ribavirin or intravenous ribavir.....
    Document: The Korean Journal of Internal Medicine Vol. 33, No. 2, March 2018 beyond the usual duration in cases of severe influenza LRTI [134, 139, 143] . Aerosolized ribavirin and intravenous immunoglobulin (IVIG) combination treatment significantly reduces RSV-LRTI-related mortality and is thus recommended by most guidelines [129, 137, 140, 141] . Although evidence is lacking, if aerosolized ribavirin cannot be used, oral ribavirin or intravenous ribavirin may be considered [129, 137, 140, 141] . A recent double-blind, placebo-controlled study of GS-5806 (presatovir), an oral RSV-entry inhibitor, involved 54 RSV-infected healthy adult volunteers who received RSV challenge intranasally. GS-5806 reduced the viral load and the severity of clinical disease [143] . Proven PIV-LRTI should be treated with aerosolized ribavirin and IVIG in combination [129, 137, 140] . Unfortunately, aerosolized ribavirin is costly and available only through the Korea Orphan & Essential Drug Center in Korea, so its use is limited. No antiviral is available to treat CRV, rhinovirus, human metapneumovirus, and bocavirus LRTIs, so supportive care is the mainstay.

    Search related documents:
    Co phrase search for related documents
    • aerosolized ribavirin and evidence lack: 1
    • aerosolized ribavirin and intravenous immunoglobulin: 1, 2
    • aerosolized ribavirin and intravenous immunoglobulin aerosolized ribavirin: 1, 2
    • aerosolized ribavirin and rsv entry: 1
    • aerosolized ribavirin and rsv entry inhibitor: 1
    • clinical disease and combination treatment: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19
    • clinical disease and evidence lack: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
    • clinical disease and intravenous immunoglobulin: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • clinical disease and placebo control: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • clinical disease and placebo control study: 1
    • clinical disease severity and combination treatment: 1, 2, 3
    • clinical disease severity and evidence lack: 1
    • clinical disease severity and intravenous immunoglobulin: 1, 2, 3, 4
    • clinical disease severity and placebo control: 1
    • combination treatment and evidence lack: 1
    • combination treatment and intravenous immunoglobulin: 1, 2, 3
    • combination treatment and IVIG combination treatment: 1
    • combination treatment and placebo control: 1, 2, 3
    • evidence lack and intravenous immunoglobulin: 1, 2, 3